Published in Health Risk Factor Week, September 8th, 2009
have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE® smallpox vaccine. This potential new project will have no influence on the ongoing RFP-3 BARDA (Biomedical Advanced Research and Development Authority) contract for the procurement of 20 million doses of IMVAMUNE® and the licensure of the current liquid-frozen formulation, but represents an additional business opportunity.
Earlier this year BARDA published a Broad Agency Announcement (BAA) soliciting proposals for the advanced development of medical countermeasures against...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week